StockData
Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc. (PLRX) stock

PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$0.66+0.00 (+0.12%)

Close on Nov 18, 2026Market cap $40.93MP/E –Yield 0.00%

Pliant Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Pliant Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$70.90M. For fiscal 2025 it was -$128.71M. The highest annual figure on record is -$3.71M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$128.71M–
FY2024Dec 31, 2024-$159.35M–
FY2023Dec 31, 2023-$117.28M–
FY2022Dec 31, 2022-$96.39M–
FY2021Dec 31, 2021-$77.40M–
FY2020Dec 31, 2020-$38.80M–
FY2019Dec 31, 2019-$3.71M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.80M–
Q1 FY2026Mar 31, 2026-$19.23M–
Q4 FY2025Dec 31, 2025-$17.79M–
Q3 FY2025Sep 30, 2025-$21.08M–
Q2 FY2025Jun 30, 2025-$40.72M–
Q1 FY2025Mar 31, 2025-$49.13M–
Q4 FY2024Dec 31, 2024-$47.87M–
Q3 FY2024Sep 30, 2024-$33.17M–
Q2 FY2024Jun 30, 2024-$46.55M–
Q1 FY2024Mar 31, 2024-$31.76M–
Q4 FY2023Dec 31, 2023-$25.16M–
Q3 FY2023Sep 30, 2023-$36.32M–
Q2 FY2023Jun 30, 2023-$25.36M–
Q1 FY2023Mar 31, 2023-$30.44M–
Q4 FY2022Dec 31, 2022-$31.41M–
Q3 FY2022Sep 30, 2022-$19.19M–
Q2 FY2022Jun 30, 2022-$24.65M–
Q1 FY2022Mar 31, 2022-$21.14M–
Q4 FY2021Dec 31, 2021-$20.46M–
Q3 FY2021Sep 30, 2021-$22.99M–
Q2 FY2021Jun 30, 2021-$20.04M-367.7%
Q1 FY2021Mar 31, 2021-$13.91M–
Q4 FY2020Dec 31, 2020-$17.07M-146.7%
Q3 FY2020Sep 30, 2020-$16.12M–
Q2 FY2020Jun 30, 2020$7.49M–
Q1 FY2020Mar 31, 2020-$13.10M–
Q4 FY2019Dec 31, 2019$36.56M–
Q3 FY2019Sep 30, 2019-$14.92M–

More Pliant Therapeutics figures

See a number that looks wrong?